MedTrace Logo

Bioavailability of EPA/DHA in of Ruby-O and Krill Oil

NCT05438173 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2022-12-01

No results posted yet for this study

Summary

The objective of this study is to assess the relative bioavailability of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in two supplement products in healthy adult men and women.

Conditions

  • Bioavailability

Interventions

DIETARY_SUPPLEMENT

EPA + DHA Ruby-O

Subject will receive a single 1000 mg oral dose of EPA + DHA Ruby-O capsule

DIETARY_SUPPLEMENT

EPA + DHA Krill Oil

Subject will receive a single 1000 mg oral dose of EPA + DHA krill oil capsule

Sponsors & Collaborators

  • Naturmega

    collaborator UNKNOWN

  • Midwest Center for Metabolic and Cardiovascular Research

    lead OTHER

Principal Investigators

  • Kevin C Maki, PhD · MB Clinical Research & Consulting

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-11
Primary Completion
2022-09-18
Completion
2022-09-18

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05438173 on ClinicalTrials.gov